All In Biotech

Drug Trial Radar · NCT00289978

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

A 24-month, Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of Fingolimod 1.25 mg and 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Relapsing-remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Apr 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,272 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,272

Actual

Start

Jan 2006

Primary completion

Jul 2009

Study completion Jul 2009

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Feb 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the efficacy, safety, and tolerability of 2 doses of oral fingolimod (1.25 mg/day and 0.5 mg/day) compared to placebo in patients with relapsing-remitting multiple sclerosis (RRMS)

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

  • Fingolimod 1.25 mgDrug

    Patients self-administered fingolimod 1.25 mg capsules orally once daily.

  • Fingolimod 0.5 mgDrug

    Patients self-administered fingolimod 0.5 mg capsules orally once daily.

  • PlaceboDrug

    Patients self-administered a fingolimod placebo capsule orally once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Estimated Annualized Aggregate Relapse Rate (ARR)Time frame: Baseline to end of study (Month 24)

Locations

115 sites in 19 countries. Site status is shown where the registry gives one.

  • North Gosford Private Hospital

    Burrabil Avenue, Suite 17, Gosford, Australia

  • Strategic Health Evaluators

    Chatswood, Australia

  • St Vincent's Hospital Melbourne, Department of Clinical Neurosciences

    Fitzroy, Australia

  • Austin Health, Department of Neurology

    Heidelberg, Australia

  • The Queen Elizabeth Hospital

    Woodville South, South Australia, Australia

  • MS Klinik

    Boemerangstraat 2, Overpelt, Belgium

  • National Multiple Sclerose Centrum v.z.w

    Vanheylenstraat 16, Melsbroek, Belgium

  • Algemeen Ziekenhuis St. Jan, Department of Neurology

    Ruddershove, Brugge, Belgium

  • Erasme Hospital

    Route de Lennik 808, Brussels Capital, Belgium

  • CHU Charleroi, Hôpital Civil

    Boulevard Paul Janson 92, Charleroi, Belgium

  • University Hospital Gasthuisberg

    Department Neurology, Herestraat 49, Leuven, Belgium

  • AZ Alma

    Department of Neurology & Rehab-Umit, Gentsesteenweg 132, Sijsele, Belgium

  • Regionaal Ziekenhuis

    St.Trudo, Diestersteenweg 100,, St.Truiden, Belgium

  • University of British Columbia

    Me498 2211 Wesbrook Mall, Vancouver, British Columbia, Canada

  • DMSRU - Capital Health

    Halifax, Nova Scotia, Canada

  • Kingston General Hospital, MS Clinic

    Connell 7, 76 Stuart Street, Kingston, Ontario, Canada

  • Nepean Medical Center

    Ottawa, Ontario, Canada

  • St. Michael's Hospital

    Toronto, Ontario, Canada

  • Clinical Trials Office,

    Trillium Health Center, 00 Queesway West, Mississauga, Ontario, Canada

  • Hopital Maisonneuve-Rosemont, Recherche Clinique de Neurologie

    Montreal, Quebec, Canada

  • University of Saskatchewan

    Regina, Saskatchewan, Canada

  • Centrum neurologicke pece

    Jiraskova 1389, Rychnov Nad Kneznou, Czechia

  • Facultní Nemocnice Spoliklinikou Ostrava, Neurology Department

    Ostrava, Czechia

  • Military Hospital of Brno

    Department of Neurology, Zabrdovicka 3, Brno, Czechia

  • Faculty Hospital St. Anne

    First Department of Neurology, Pekarska 53, Brno, Czechia

  • Faculty Hospital

    Department of Neurology, I.P. Paulova 6, Olomouc, Czechia

  • Hospital of Pardubice

    Department of Neurology, Kyjevska 44, Pardubice, Czechia

  • Faculty Hospital

    Department of Neurology, Alej Svobody 80, Plzeň, Czechia

  • Neurologicka klinika, Fakultni nemocnice

    Kralovske Vinohrady, Srobarova 50, Prague, Czechia

  • Faculty Hospital Motol, MS Center

    Department of Neurology, V Uvalu 84, Prague 5, Czechia

  • Vseobecna fakultni nemocnice

    MS Centrum, Neurologicka Klinika, Karlovo Namesti 32, Praha 2, Czechia

  • MS Centrum

    Neurology Department of Hospital Teplice, Duchcovska 53, Teplice, Czechia

  • Suomen Terveystalo/ Päänsärkykeskus, Tampere

    Hämeenkatu 18, 6th Fl., Tampere, Finland

  • Turku University Hospital, Neurology Department 799

    Kiinanmyllynkatu 11- 14, Turku, Finland

  • Hyvinkään sairaala

    Neurologian Poliklinikka, Sairaalankatu 1, Hyvinkää, Finland

  • Helsinki Headache Center Postitalon Lääkäriasema

    Mannnerheiminaukio 1 B 2 Floor, Helsinki, Finland

  • Finnish Special Neurology Center Ltd.

    Brahenkatu 11 D,, Turku, Finland

  • CHU La Timone

    Service Neurologie, Boulevard Jean Moulin, Marsielle Cedex 5, France

  • Investigational Site

    Berlin, Germany

  • Investigational Site

    Berlin, Germany

Showing 40 of 115 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.